151 related articles for article (PubMed ID: 3395140)
1. [A case of advanced breast cancer successfully treated with combined tamoxifen and epitiostanol].
Konishi Y; Morimoto T; Komaki K; Yamakawa T; Mituyama N; Tanaka T; Oomine Y; Monden Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2163-7. PubMed ID: 3395140
[TBL] [Abstract][Full Text] [Related]
2. [Present status of endocrine therapy of breast cancer: a surgeon's view].
Nomura Y
Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405
[TBL] [Abstract][Full Text] [Related]
3. [Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
Une Y; Sato Y; Kagaya H; Miyata S; Matsuoka S; Uchino J; Yakura Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2778-81. PubMed ID: 6548892
[TBL] [Abstract][Full Text] [Related]
4. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
5. Segmental mastectomy and tamoxifen alone provide adequate locoregional control of breast cancer in elderly women.
Yeh S; Tan LR; O'Connell TX
Am Surg; 1997 Oct; 63(10):854-7. PubMed ID: 9322656
[TBL] [Abstract][Full Text] [Related]
6. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
[TBL] [Abstract][Full Text] [Related]
8. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Lee JH; Recht A
J Clin Oncol; 2003 Jun; 21(12):2260-7. PubMed ID: 12805324
[TBL] [Abstract][Full Text] [Related]
9. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
Kiman K; Suzuki S; Satomi T; Sakonji M; Nihei M; Tanaka T; Kimijima I; Abe R
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
[TBL] [Abstract][Full Text] [Related]
13. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
14. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and hormone therapy of metastatic breast cancer.
Paterson AH
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):631-3. PubMed ID: 3835708
[No Abstract] [Full Text] [Related]
16. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Nicolini A; Carpi A
Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
19. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.
Ahn PH; Vu HT; Lannin D; Obedian E; DiGiovanna MP; Burtness B; Haffty BG
J Clin Oncol; 2005 Jan; 23(1):17-23. PubMed ID: 15545666
[TBL] [Abstract][Full Text] [Related]
20. [A case of recurrent breast cancer responding to long-term administration of tamoxifen].
Yayoi E; Kobayashi T; Inaji H; Maeura Y; Mori T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1683-6. PubMed ID: 6433801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
